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ABSTRACT
Examination of cross-protection and type replacement after human papillomavirus (HPV) vaccine
introduction is essential to guide vaccination recommendations and policies. The aims of this study
were to examine trends in non-vaccine-type HPV: 1) genetically related to vaccine types (to assess for
cross-protection) and 2) genetically unrelated to vaccine types (to assess for type replacement), among
young women 13–26 years of age during the 11 years after HPV vaccine introduction. Participants were
recruited from a hospital-based teen health center and a community health department for four cross-
sectional surveillance studies between 2006 and 2017. Participants completed a survey that assessed
sociodemographic characteristics and behaviors, and cervicovaginal swabs were collected and tested for
36 HPV genotypes. We determined changes in proportions of non-vaccine-type HPV prevalence and
conducted logistic regression to determine the odds of infection across the surveillance studies,
propensity-score adjusted to control for selection bias. Analyses were stratified by vaccination status.
Among vaccinated women who received only the 4-valent vaccine (n = 1,540), the adjusted prevalence
of HPV types genetically related to HPV16 decreased significantly by 45.8% (adjusted odds ratio
[AOR] = 0.48, 95% confidence interval [CI] = 0.31–0.74) from 2006–2017, demonstrating evidence of
cross-protection. The adjusted prevalence of HPV types genetically related to HPV18 did not change
significantly (14.2% decrease, AOR = 0.83, 95% CI = 0.56–1.21). The adjusted prevalence of HPV types
genetically unrelated to vaccine types did not change significantly (4.2% increase, AOR = 1.09,
CI = 0.80–1.48), demonstrating no evidence of type replacement. Further studies are needed to monitor
for cross-protection and possible type replacement after introduction of the 9-valent HPV vaccine.
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Introduction
Human papillomavirus (HPV) infection causes cervical cancer,
the second most commonly diagnosed cancer in women.1 In
2012, GLOBOCAN reported 528,000 new cases of cervical can-
cer globally.1 HPV infection may cause other anogenital and
oropharyngeal cancers in both women and men. It is estimated
that 90–93% of anal cancers, 36–40% of penile cancers, 40–64%
of vaginal cancers, 40–51% of vulvar cancers, and 12–63% of
oropharyngeal cancers are attributable to HPV.2-4 Three pro-
phylactic HPV vaccines have been licensed: a 2-valent vaccine
(2vHPV) that prevents HPV16 and 18; a 4-valent vaccine
(4vHPV) that prevents HPV6, 11, 16 and 18; and a 9-valent
vaccine (9vHPV) that prevents HPV16, 18, 6, 11, 31, 33, 45, 52,
and 58.5 HPV16, of the Alphapapillomavirus 9 species (A9), and
HPV18, of the Alphapapillomavirus 7 species (A7), are the most
carcinogenic HPV types, causing approximately 70% of cervical
cancers, and are targeted by all three licensed HPV vaccines.6
Studies have demonstrated that HPV vaccines not only have
high efficacy in clinical trials, but also high effectiveness in real-
world settings: we have demonstrated that 4-valent vaccine-type
HPV detection decreased from 35%-6.7% (80.9% decline)
among vaccinated women, demonstrating vaccine effectiveness,
and decreased from 32.4%-19.4% (40% decline) among unvac-
cinated women, demonstrating herd protection.7
Vaccination may also result in cross-protection; that is, pro-
tection against HPV types genetically related to vaccine types,
because HPV16 is genetically related to other A9 types and
HPV18 is genetically related to other A7 types. It has been
hypothesized that anti-HPV16 and anti-HPV18 antibodies gen-
erated by vaccination may bind to and neutralize HPV virions
genetically related to HPV16 or HPV18, given the polyclonal
immune response to vaccination.8 Several HPV vaccine clinical
trials have shown evidence of cross-protection; however, less is
known about cross-protection outside of the trial setting.
Information about cross-protection in real-world settings is
important for clinical- and cost-effectiveness assessments and
health policy decisions, given that cross-protection could
increase vaccine effectiveness. Long-term surveillance is essential
given that there is some evidence from clinical trials that cross-
protection wanes over time.9,10
In contrast to cross-protection, type replacement could
lead to an increase in non-vaccine-type HPV which could
decrease vaccine effectiveness.11 This may occur if the ecolo-
gical niche that was occupied by HPV16 and HPV18 becomes
vacated due to a decrease in vaccine-type.11 Currently, there is
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no definitive evidence of type replacement after HPV vaccine
introduction.12,13 This is expected, as HPVs are genetically
stable DNA viruses that have co-evolved with their specific
vertebrate host, and have a very low rate of mutations, at
about one nucleotide every 1,000 years.13,14 However, it is
important to exclude type replacement after HPV vaccine
introduction because type replacement has been documented
after introduction of other vaccines, including Haemophilus
influenza and Streptococcus pneumococcal vaccines,15-17 and
because the evidence regarding type replacement after HPV
vaccine introduction is not conclusive. Some studies suggest
a possible competitive advantage for non-vaccine types or an
increase in non-vaccine-types after vaccine introduction,18-21
supporting continued monitoring for type replacement. To
determine accurately whether emerging type-replacement is
occurring, it is important to examine non-vaccine-type HPV
that is genetically unrelated to vaccine-type HPV, as cross-
protection may decrease the prevalence of types genetically
related to those in the vaccines, which could mask an increase
in non-vaccine-type HPV.
In order to assess cross-protection and type-replacement in
a community setting, we conducted surveillance studies examin-
ing the prevalence of non-vaccine-type HPV before and during
the 11 years after widespread HPV vaccine introduction. The
first aim was to examine trends in the prevalence of HPV types
genetically related to those targeted by the 4vHPV vaccine. We
hypothesized, based on clinical trials data,8,9 that there would be
a significant decrease in the prevalence of HPV types genetically
related to HPV16 (HPV31, 33, 35, 52, 58, 67) and HPV18
(HPV39, 45, 59, 68, 70) among young women who received
the 4vHPV vaccine. The second aim was to assess for emerging
type replacement by examining trends in the proportion of
young women infected with non-vaccine-type HPV. We
hypothesized we would not observe an increase in non-vaccine-
type HPV genetically unrelated to vaccine-type HPV.
Results
A total of 1,580 participants were enrolled across four surveil-
lance studies, and 1,540 were included in these analyses: 40
(2.5%) were excluded because they had received at least one
dose of the 9-valent HPV vaccine. Between 95% and 98% of
those approached agreed to participate across the surveillance
studies. Participant characteristics across the four surveillance
studies are shown in Table 1. The mean age of participants
across the four studies was 18.7–19.2 years, 69.9%-76.7%
identified as African American or Multiracial, and 52.8%-
70.6% reported having Medicaid health insurance. Between
70.1% and 77.8% of all participants reported sexual initiation
between 14 and 17 years of age, 78%-87.8% reported having
more than one lifetime male partner, and 64.3%-73.9%
reported not using a condom at last sexual intercourse.
Vaccination rates increased from 0% in study 1 to 59.2% in
study 2, 71.5% in study 3, and 82.5% in study 4.
Demographic characteristics, gynecologic history, and sexual
behaviors were compared across the four studies (Table 1). Due
to several significant differences across studies, variables were
balanced using propensity score weighting. After propensity
score weighting, there were no significant differences in variables
across studies. When we compared the prevalence of baseline
variables across the four study waves by vaccination status,
before and after propensity score weighting, we found that the
only variable that was not balanced was Appalachian back-
ground among unvaccinated women. Therefore, Appalachian
background was included in the logistic regression model for
unvaccinated women only. The β-globin control in the Roche
Linear Array test, indicating adequate DNA for PCR amplifica-
tion, was positive in 98.8% to 100% of all samples across the four
studies.
The proportions of women (all, vaccinated, and unvaccinated)
who were positive for non-vaccine-type HPV genetically related
to HPV16 and HPV18, and positive for types not included and
genetically unrelated to those in the vaccine, are shown in Table 2.
The propensity score-adjusted proportion of all women with non-
vaccine-type HPV genetically related to HPV16 did not change
significantly from studies 1 to 4. However, the adjusted proportion
of vaccinated women with non-vaccine-type HPV genetically
related to HPV16 decreased significantly from 22.7% to 12.3%
(45.8% decrease) from studies 1 to 4 while the adjusted proportion
of unvaccinated women with non-vaccine-type HPV genetically
related to HPV16 increased significantly from 22.3% to 35.3%
(58.3% increase) from studies 1 to 4. The adjusted proportion of
all women who were positive for non-vaccine-type HPV geneti-
cally related to HPV18 did not change significantly for all women
or for vaccinated women, but decreased significantly from 20.2%
to 6.3% (68.8% decrease) among unvaccinated women. There
were no significant changes in non-vaccine-type HPV genetically
unrelated to A9 and A7 species among all, vaccinated, and unvac-
cinated women except for a transient increase from study 1 to
study 2.
The results of unadjusted and adjusted logistic regression
models, comparing the odds of infection with non-vaccine-
type HPV in studies 1, 2 and 3 with study 4, are shown in
Table 3. The odds of non-vaccine-type HPV genetically related
to HPV16 was significantly lower in study 4 vs. 1 (OR 0.48, 95%
CI 0.31–0.74) among vaccinated women, and the odds of non-
vaccine-type HPV genetically related to HPV18 was significantly
lower in study 4 vs. 1 among unvaccinated women (OR 0.25,
95% CI 0.09–0.75). The odds of infection with non-vaccine-type
HPV genetically unrelated toHPV16 andHPV18 did not change
significantly from study 1 to 4.
Discussion
In this study, we investigated trends in the prevalence of HPV
types genetically related to oncogenic HPV types targeted by
4vHPV (to assess for cross-protection), and the prevalence of
HPV types genetically unrelated to 4vHPV (to assess for type-
replacement), during the 11 years after HPV vaccine intro-
duction, from 2006–2017. To our knowledge, this is the first
U.S. study to assess cross-protection and type replacement
more than 10 years after HPV vaccine introduction in a real-
world setting, and extends the findings of our previous
study22 which assessed these outcomes from 2006–2014. In
separate analyses, we examined trends in vaccine-type HPV to
assess effectiveness and herd protection during this time
period.7
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Our findings demonstrated evidence of cross-protection
against non-vaccine-type HPV genetically related to HPV16: vac-
cinated women in study 4 vs. study 1 had 0.48 times the odds of
infection with a genetically related type. We did not find a similar
reduction in non-vaccine-type HPV genetically related to HPV18
among vaccinated women. Although we found a significant
decrease in HPV types genetically related to HPV18 in unvacci-
nated women, these data should not be considered conclusive as
the number of unvaccinated women with these HPV types was
very low (only 4 unvaccinated women were positive for an HPV
type genetically related to HPV18). Cross-protection has been
demonstrated in clinical trials, though efficacy against non-
vaccine types is lower than among vaccine types, and wanes over
time.9 Malagon et al. conducted a meta-analysis of 2-valent and
4-valent HPV vaccine clinical trials to examine cross-protection
against persistent HPV31, 33 and 45 infections and precancers
associated with these types.9 The authors found that the 4-valent
vaccine was efficacious against outcomes associated with HPV31,
and the 2-valent vaccine against outcomes associatedwithHPV31,
33, and 45. Efficacy against persistent infections with HPV31 and
45 decreased over time, suggesting waning cross-protection.
A 2015 meta-analysis demonstrated an overall decrease in
HPV31 and 33 (genetically related to HPV16) and 45 (genetically
related to HPV18), among 13–19 year-old girls in real-world
settings; however, these reductions were not associated with vac-
cination status,23 and similar reductions were not observed among
20–24 year-old women. A 2016 meta-analysis similarly demon-
strated evidence for cross-protection against HPV31 among
young women <20 years of age.20 In our study, we observed
evidence of cross-protection against HPV16 but not HPV18.
One explanation may be lower neutralizing antibodies against
the A7 types other than HPV18 vs. the A9 types other than
HPV16. In a study of 13–14 year-old girls who had received the
2-valentHPVvaccine series,Draper et al. found that fewer samples
were positive for neutralizing antibodies against non-vaccineHPV
types from the A7 than the A9 species group.24
In this study population, we did not find evidence of type
replacement: there was no significant increase in types not
included and genetically unrelated to those in the vaccine in all
women, vaccinated women, or unvaccinated women. We have
recently observed a significant increase in the five additional HPV
types included in the 9-valent vaccine but not in the 4-valent
vaccine in unvaccinated women (unpublished data). These types
included HPV types genetically related to HPV16 and HPV18,
thus reinforcing the importance of considering genetically related
types when exploring type replacement. Other studies have simi-
larly found no conclusive evidence of type replacement in real-
world settings, but some have identified signals that confirm the
importance of continued surveillance.18-21,25,26 Yang et al. exam-
ined concurrence of multiple HPV infections in 47,617 women
undergoing cervical cancer screening, and found a negative inter-
action between HPV16 and other HPV types among women with
abnormal cytology, but not among those with normal cytology,
suggesting that type replacement in vaccinated women is unlikely
in the general population.21 Tota et al. compared acquisition and
clearance of 30HPV types, using data from three studies involving
3200 women. Vaccine-type HPVs did not appear to compete with
other types, suggesting that HPV type replacement was unlikely.26
Carozzi et al. found no statistically significant differences in non-
vaccine-type HPV in unvaccinated vs. vaccinated women after
vaccine introduction in Italy, suggesting no evidence of type
replacement.25 In contrast, among a sample of 3,183 Finnish
women, Merikukka et al. demonstrated a possible competitive
advantage for HPV33 over other genital HPV types in the unvac-
cinated population, and suggested that HPV33 should be mon-
itored for type replacement after widespread HPV vaccination.19
Table 3. Comparisons of the proportions of women positive for ≥ 1 non-vaccine HPV type, ≥ 1 A9 species except HPV16, and ≥ 1 A7 species except HPV18, across
the four surveillance studies, stratified by vaccination status: results of logistic regression analyses unadjusted and adjusted for propensity scores.a,b.
Study 4 vs.1 Study 4 vs. 2 Study 4 vs. 3
Unadjusted ORc,d (95% CIe)
Adjusted OR
(95% CI)
Unadjusted OR
(95% CI)
Adjusted OR
(95% CI)
Unadjusted OR
(95% CI)
Adjusted OR
(95% CI)
A9 species except HPV16f
All 0.58 (0.40–0.84) 0.70 (0.49–1.02) 0.45 (0.31–0.64) 0.55 (0.39–0.78) 0.93 (0.64–1.38) 1.05 (0.72–1.53)
Vaccinated 0.54 (0.36–0.80) 0.48 (0.31–0.74) 0.39 (0.26–0.60) 0.35 (0.22–0.54) 0.98 (0.62–1.55) 0.77 (0.48–1.25)
Unvaccinated 0.80 (0.42–1.54) 1.78 (0.99–3.21) 0.66 (0.33–1.33) 1.31 (0.70–2.47) 0.97 (0.46–2.08) 1.41 (0.71–2.76)
A7 species except HPV18g
All 0.83 (0.58–1.20) 0.74 (0.51–1.07) 0.54 (0.39–0.76) 0.45 (0.32–0.63) 0.77 (0.54–1.09) 0.63 (0.44–0.90)
Vaccinated 0.98 (0.68–1.42) 0.83 (0.56–1.21) 0.53 (0.36–0.77) 0.43 (0.29–0.64) 0.90 (0.61–1.32) 0.82 (0.55–1.23)
Unvaccinated 0.24 (0.09–0.69) 0.25 (0.09–0.75) 0.22 (0.07–0.63) 0.21 (0.07–0.65) 0.23 (0.08–0.69) 0.17 (0.05–0.51)
Non-vaccine-type HPV genetically unrelated to A7 and A9 speciesh
All 1.15 (0.86–1.55) 1.29 (0.96–1.73) 0.67 (0.50–0.90) 0.81 (0.60–1.08) 1.00 (0.75–1.33) 1.05 (0.78–1.40)
Vaccinated 1.14 (0.84–1.54) 1.09 (0.80–1.48) 0.58 (0.41–0.83) 0.70 (0.49–0.99) 0.96 (0.69–1.33) 0.97 (0.69–1.35)
Unvaccinated 1.25 (0.73–2.13) 1.66 (0.95–2.90) 0.87 (0.48–1.55) 1.14 (0.62–2.07) 1.13 (0.61–2.10) 1.06 (0.56–2.02)
aVariables included in the propensity score analysis included: enrollment site, age, race, Hispanic ethnicity, health insurance plan, male partners in the past three
months, whether one’s main partner is male, history of anal sex, condom use with main partner, condom use at last sexual intercourse, and history of cigarette
smoking. Appalachian descent was used as an additional covariate in unvaccinated women after propensity score adjustment. The odds ratio for Appalachian
descent for A9 species was 0.5 (CI = 0.21–1.38), for A7 species was 0.77 (CI = 0.32–1.87), and for non-vaccine-type unrelated to A7 and A9 species was 1.34
(CI = 0.67–2.66).
bNo women were vaccinated in study 1, 242 (59.2%) were vaccinated in study 2, 286 (71.5%) were vaccinated in study 3, and 297 (82.5%) were vaccinated in study 4.
cOR = odds ratio.
dBold indicates p ˂ 0.05.
eCI = confidence interval.
fPositive for ≥ 1 HPV type of the following: 31, 33, 35, 52, 58 and/or 67.
gPositive for ≥ 1 HPV type of the following: 39, 45, 59, 68 and/or 70.
hPositive for ≥ 1 HPV type other than 6, 11, 16, 18, 31, 33, 35, 39, 45, 52, 58, 59, 67, 68, and/or 70.
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Mesher et al. examined type-replacement in a meta-analysis of 9
real-world studies including data for 13,886 girls and women
≤19 years of age and 23,340 women 20–24 years of age.20 The
analyses demonstrated slight increases in two non-vaccine high-
riskHPV types, HPV39 andHPV52.20 Finally, Gray et al. explored
whether type-replacement occurred in a community-randomized
trial of the 2-valent HPV vaccine, and identified a possible signal
indicated by clustering betweenHPV39 andHPV16orHPV18/45,
and between HPV51 and HPV16 or HPV18/45, suggesting that
the prevalence of HPV39 and HPV51 should be monitored after
vaccine introduction.18
This study has several strengths, including collection of
epidemiological data on HPV prevalence before and during
the 11 years after HPV vaccine introduction, and collection of
detailed participant behavioral data, allowing us to adjust for
differences across studies using propensity score weighting.
This study also has several limitations, including the fact that
participants were recruited from clinical settings and most
reported their race as underrepresented minority. Therefore,
the findings cannot be generalized to the U.S. population;
however, the findings do provide important information
about a population at elevated risk for morbidity and mortal-
ity due to HPV-related cancers. In addition, inadequate sta-
tistical power may have contributed to negative findings for
some outcomes. The parent study was designed to power for
vaccine-type HPV outcomes, while non-vaccine type HPV
was a secondary outcome. We did find statistically significant
results for A9 species except HPV16, indicating that the
sample size was sufficient to determine whether there was
a statistically significant change from study 1 to 4, but not
for A7 species except for HPV18 and for non-vaccine-type
HPV genetically unrelated to A7 and A9 species. A post-hoc
power analysis demonstrated that the study had 80% power to
detect a decrease of 8.6% for A7 species except HPV18 from
study 1 to 4, and an increase of 10.8% for non-vaccine-type
HPV genetically unrelated to A7 and A9 species from study 1
to 4. Therefore, the study was not adequately powered for the
observed small differences for A7 species except HPV18
(−3.3%) and non-vaccine-type HPV genetically unrelated to
A7 and A9 species (+2.1%), but was powered adequately to
detect larger and more clinically meaningful differences.
Another limitation of this study is that although the propen-
sity score analysis adjusts for differences in measured char-
acteristics related to HPV infection, it may not adjust for
unmeasured characteristics. Finally, only a small proportion
of women in this study had received the 9-valent HPV vac-
cine, precluding an examination of cross-protection and type-
replacement after widespread uptake of the 9-valent vaccine.
It will be important to assess effectiveness, cross-protection
and type-replacement after more robust uptake of the 9-valent
vaccine.
In summary, we found evidence for cross-protection against
non-vaccine-type HPV genetically related to HPV16, but no
evidence for type-replacement, during the 11 years after 4-valent
vaccine introduction in a community. Given that cross-
protection appears to wane in HPV vaccine clinical trials, con-
tinued surveillance for cross-protection as well as research exam-
ining whether cross-protection differs by age, vaccine type, and
other factors will be important to guide clinical- and cost-
effectiveness analyses and related public health and policy deci-
sions. Although there has been no conclusive evidence to date of
type replacement after HPV vaccine introduction, the possible
signals of an increase in non-vaccine-type HPV after vaccine
introduction and the fact that type replacement has occurred
after introduction of other vaccines15-17 suggest that type repla-
cement should continue to be monitored in future surveillance
studies, especially after more widespread uptake of the 9-valent
HPV vaccine.
Materials and methods
Study design
We enrolled young women 13–26 years of age in four cross-
sectional surveillance studies: 2006–2007 (N = 371),
2009–2010 (N-409), 2013–2014 (N = 400), and 2016–2017
(N = 400). Participants were recruited from a hospital-based
Teen Health Center and the Cincinnati Health Department,
using a sequential recruitment strategy. Adolescent and young
adult women between 13 and 26 years of age with a history of
sexual contact were eligible to participate. Women who parti-
cipated in a previous study were ineligible for re-enrollment.
The study was approved by the hospital and Health
Department Institutional Review Boards and written
informed consent from each participant was obtained. Only
individuals who received the 4vHPV vaccine or did not
receive any HPV vaccine were included in this analysis,
because the 9vHPV vaccine was only available to participants
in the fourth study and only 40 (2.5%) of participants received
the 9vHPV vaccine.
Study procedures
We implemented identical study procedures across all four
waves. Participants completed a survey instrument that
assessed sociodemographic characteristics (i.e. race, ethnicity,
socioeconomic status, etc.), behaviors (substance use, sexual
behaviors), reproductive health history, and participant
knowledge about HPV and HPV vaccines. Cervicovaginal
swabs were collected from each participant. Either the clin-
ician or the participant collected the sample, using a standard
procedure. Each sample was evaluated using the Roche Linear
Array test. The Linear Array test is a qualitative test that uses
biotinylated primer sets PGM09/PGMY11 and PC04/GH20
for simultaneous amplification of fragments of the HPV L1
gene and human beta-globin gene, respectively. After PCR
amplification, genotyping is performed using a strip coated
with HPV type-specific and beta-globin-specific oligonucleo-
tide probes, to identify 36 HPV genotypes.27,28 We verified
participants’ vaccination history using an electronic medical
record database and a statewide vaccine registry; validity of
vaccination history assessment is described in a previous
manuscript.29
Statistical analyses
We used SAS version 9.3 (SAS Institute, Cary, NC) to analyze
data. Similarly to a previous analysis,22 our analytic strategy was
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to determine changes in proportions of non-vaccine-type HPV
prevalence among vaccinated (women who had received at least
one vaccine dose) and unvaccinated women across four surveil-
lance studies. Outcome variables for Aim 1 were any A9 HPV
types genetically related to HPV16 but not targeted by the
4vHPV vaccine (HPV31, 33, 35, 52, 58, 67) and any A7 HPV
types genetically related to HPV18 but not targeted by the
4vHPV vaccine (HPV39, 45, 59, 68, 70). The outcome variable
for Aim 2 was any HPV types that were not genetically related to
those in the vaccine (i.e. positive for ≥ 1 HPV type other than 6,
11, 16, 18, 31, 33, 35, 39, 45, 52, 58, 59, 67, 68, and/or 70). Only
HPV types genetically unrelated to those included in the vaccine
were assessed, because cross-protection may decrease the pre-
valence of genetically related non-vaccine-type HPV, obscuring
an increase in non-vaccine-type HPV. Prevalence of HPV types
was based on the above groupings, i.e., as composite outcome
variables.
We compared participant characteristics across the four
surveillance studies using univariable methods (chi-square,
Fisher’s exact, ANOVA or Kruskal Wallis), to determine if
sociodemographic characteristics, behaviors, and reproductive
health history differed across these studies. The results of
these analyses demonstrated statistically significant differences
between studies for some of the variables; therefore, we con-
ducted a propensity score analysis based on inverse probabil-
ity of treatment weighting30,31 as we have done in previous
studies.22,32,33 A propensity score analysis adjusts for selection
bias, simulating the characteristics of a randomized controlled
trial34 which allows one to assess whether differences in non-
vaccine-type HPV prevalence across the studies were due to
vaccine introduction, in contrast to confounding variables.
The prevalence of non-vaccine-type HPV was compared
across the four studies, stratified by vaccination status, before
and after propensity weighting. Vaccination status was
defined as follows: 1) all women across the four studies, 2)
vaccinated women (all women in study 1, who were all
unvaccinated, and vaccinated women in studies 2, 3, and 4),
and 3) unvaccinated women across the four studies. Logistic
regression models were performed for all, vaccinated, and
unvaccinated women in order to determine the odds of infec-
tion with non-vaccine-type HPV across the four studies,
before and after propensity weighting.
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